Sino Biopharmaceutical (HKG:1177) said data from two phase I studies of TQC3721 dry powder inhaler was presented at the 2026 annual meeting of the European Respiratory Society.
The clinical trial tested the safety and efficacy of the inhaler, developed by unit Chia Tai Tianqing Pharmaceutical Group, in patients with chronic obstructive pulmonary disease, according to a Monday filing with the Hong Kong bourse.